R Polychondritis

⏳ Just a few days to go! #RareDiseasesForum2026 As discussions advance on several key EU rare disease policy initiatives, how can Europe ensure a more coordinated and equitable approach for patients? 📅 21 April, Brussels 👉 go.eurordis.org/forum2026

People with systemic autoimmune and rheumatic diseases are at higher risk of adverse pregnancy and perinatal outcomes. Narrative review in AC&R describes approaches to reproductive health that provide a potential framework for high-quality care in a rheumatology context doi.org/10.1002/acr.80…

Coexistence of Relapsing Polychondritis and Crohn's Disease: Clinical Insights from a Rare Case pubmed.ncbi.nlm.nih.gov/41753295/?utm_…

✅ Do you have relapsing #polychondritis? Did you participate to our study about the main domains of life impacted by the disease? If so, you can discover the FULL RESULTS of the 274 participants in our most recent paper by the RP group of @ERN_ReCONNET at:doi.org/10.1186/s13023…

Today we will learn about... Category: USMLE Step 1 > Physiology > Biostatistics & Epidemiology/Population Health A 57-year-old man with osteoarthritis, prior tibial osteomyelitis (surgically debrided years ago), gastroparesis, relapsing polychondritis in remission, and Chiari I malformation becomes confused after dozing in his attached garage while waiting for a delivery. Two household members simultaneously develop throbbing headaches and nausea. He owns several exotic pets. On arrival he is somnolent but arousable, oriented only to name; temperature 36.2°C, pulse 68/min, respirations 20/min, blood pressure 133/99 mm Hg, and pulse oximeter saturation 60% on room air with warm well-perfused hands. Skin color is normal without flushing or cyanosis; lungs are clear; no stridor or wheeze; heart sounds regular; abdomen soft and nontender; no pedal edema; neurologic exam shows no focal deficits. He denies drug use. A fingerstick glucose is 118 mg/dL. Portable chest radiograph shows no consolidation or edema; a 12-lead ECG shows normal sinus rhythm without ischemic changes. A CBC and basic metabolic panel are within reference; TSH is within reference. A urine and serum toxicology screen has been sent; initial troponin is normal. No carboxyhemoglobin or methemoglobin level has been drawn yet. Prior chart data over several years include: knee arthroscopy for culture-negative synovitis; synovial fluid microscopy without crystals; benign oral lesion cytology by in situ hybridization; a negative urine and serum toxicology panel 6 months ago; benign thyroid FNA; SPECT of the tibia compatible with quiescent remodeling; audiometry with high-frequency sensorineural loss; negative Lyme Western blot; diagnostic paracentesis for postoperative fluid years ago with sterile culture; MRI brain showing Chiari I without syrinx; sleep study with mild OSA; two prior CT heads normal; sputum cultures during past antifungal monitoring with no growth; spirometry normal; EMG showing length-dependent axonal neuropathy; echocardiogram normal; bone scan without active osteomyelitis; diagnostic laparoscopy showing adhesions; gallium scan negative for occult infection. Staff prepare for head CT. The resident notes the striking mismatch between very low pulse oximetry and otherwise stable color, perfusion, lungs, and neurologic examination, alongside simultaneous household symptoms after a garage nap. What is the single most appropriate immediate action to prioritize patient safety and measurement validity before additional imaging? **Repeat pulse oximetry on multiple digits for 10 minutes to confirm the 60% reading before giving oxygen or ordering laboratory testing.** **Give high‑dose IV methylprednisolone for a possible relapsing polychondritis airway flare prior to assessing gas carriage or initiating oxygen therapy.** **Proceed directly to emergent noncontrast head CT without oxygen, because imaging speed outweighs physiologic correction when oximetry is unreliable.** **Administer 100% oxygen immediately by non‑rebreather mask and obtain an arterial blood gas with laboratory co‑oximetry to measure carboxyhemoglobin and methemoglobin.** 🎬 Watch the video explanation: youtube.com/watch?v=d7yZjv… The answer and explanation will be shared as a reply to this post later on. Visit endlessmedical.academy/auth?hash=0e88… to discover the correct answer and detailed explanation right now. #Physiology #MCQ #USMLEStep1 #EndlessMedical #MultipleChoiceQuestions #BiostatisticsEpidemiologyPopulationHealth #EndlessMedicalAcademy #EndlessMedicalcom #Medical #MedicalEducation Dig deeper on this topic at endlessmedical.ai, where multiple AI models debate, cross-check references, and verify calculations to give you the most updated and accurate medical information with minimal hallucinations and errors. Further reading: 1. Clinical Guidance for Carbon Monoxide Poisoning Following Disasters and Severe Weather - Centers for Disease Control and Prevention - (2024) - by Centers for Disease ... Confidence: 100% Educational value: Clarifies pitfalls of pulse oximetry in CO poisoning and prioritizes oxygen therapy and carboxyhemoglobin measurement before other testing. cdc.gov/carbon-monoxid… 2. Pulse Oximeters for Medical Purposes: Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations (Draft) - U.S. Food and Drug Administration - (2025) - by U.S. Food and Drug A... Confidence: 100% Educational value: Helps learners understand when pulse oximetry is unreliable and why confirmatory co-oximetry is needed. fda.gov/medical-device… 3. Racial Bias in Pulse Oximetry Measurement - New England Journal of Medicine - (2020) - by Sjoding MW, Dickson ... Confidence: 100% Educational value: Highlights device bias and limitations, emphasizing the need for confirmatory measurements when accuracy is critical. pubmed.ncbi.nlm.nih.gov/33326721/ Links to sources are provided for optional further reading only. *Generated by AI. May contain errors. Use at own risk. Full disclaimer: endlessmedical.academy/auth?d

A Case Report of Relapsing Polychondritis Combined With Lupus Nephritis pubmed.ncbi.nlm.nih.gov/41792946/?utm_…

Advancing access to cross-border healthcare in the EU. 📅 26 March High-Level Conference on Patients’ Rights & ERNs Key topics: cross-border rights, border regions, rare diseases. 🔗bit.ly/HLC_PatientsRi… #CrossBorderHealthcare #EUHealth #PatientRights #RareDiseases #ERNReCONNET

✅ Did you participate in the initial study about impaired domains of #QUALITYOFLIFE in #POLYCHONDRITIS, that we did a year ago? We asked to describe the BIGGEST IMPACT of the disease upon your DAILY LIFE. Well, I'm happy to report that it has just been ACCEPTED FOR PUBLICATION👍

Data and digital health are transforming #rarediseasecare.🧬 From Electronic Health Records to safe telemedicine and better data sharing, EURORDIS is working to improve diagnosis, research and access to care across Europe. 👉 Learn more about our work: go.eurordis.org/DigitalHealth

What happens when young rare disease advocates from across the world are given the space to speak, connect and lead? 👉 Read the #RaisingYouthVoices2026 article here: go.rarediseaseday.org/article #RareDiseaseDay #PatientAdvocacy

It’s #RareDiseaseDay 2026! 🎉 This #RDD2026, find our report, ‘Equity for Rare: Delivering fair healthcare systems for people with rare conditions’, our 4 inequity info sheets and our community-generated equity illustration on our webpage: ow.ly/QJbj50YmyVz

🌍 It’s #RareDiseaseDay 2026! 💜 Today we stand with the 300 million people living with a rare disease. Together, we’re showing our colours, raising awareness, and inspiring change by talking about what equity means to us. 👉 Read more: go.rarediseaseday.org/NEWS

📣 Call for young rare disease advocates! ERDERA is inviting young patients aged 12–21 to join the in‑person training in Paris on 23–25 April 2026. 🔗 Find out more and apply: loom.ly/yaURaLI ⏳ Application deadline: 8 March 2026 #ERDERA #RareDisease

On Feb. 23, the @FDA will host its virtual #RareDiseaseDay event. #RareDisease patients and advocates, don’t miss it! Learn how patient engagement, real-world data, and #AI tools ensure patient voices continue to shape #FDA decisions. RSVP: bit.ly/4abBNRD

⏰ Here’s what some of our #RaisingYouthVoices2026 Regions Reps are planning for #RareDiseaseDay! With 11 days to go, find out how you can #GetInvolved in the campaign. 🔗 Learn more: go.rarediseaseday.org/RDD

📢 Reminder: Expressions of Interest close 26 February! #EURORDIS is launching a European Regional Task Force to help shape a European Blueprint for Rare Diseases and inform policy discussions ahead of #ECRD2026. Learn more & apply: go.eurordis.org/regional-task-…

✅ Thank YOU to the 250 participants with relapsing #polychondritis who have participated to the validation phase of the #RPQoL 🙏 I have analyzed the main data yesterday and can assure you we have a VERY ROBUST instrument for assessing #Quality_of_life in #RP. More, very soon...

In collaboration with the members of our Social Policy Action Group (SPAG), we have responded to the midterm review of the European Strategy for the Rights of Persons with Disabilities to ensure the inclusion of all voices in the review. Full response 👇 go.eurordis.org/tvRhTw

Register for #RareDiseaseDay @ The National Institutes of Health! The @NIH is hosting a free, hybrid #RDDNIH event on Feb 27 about the latest stories, challenges, and opportunities in #RareDisease treatment research. RSVP: go.nih.gov/zX38wa4

Take meaningful action this #RareDiseaseDay. Use our Proclamation Toolkits to ask local or state leaders to recognize February 28, 2026, as Rare Disease Day. Check out these resources here: bit.ly/49BBMmQ #RareDiseaseAwareness #ShowYourStripes #RareDisease